As of Dec 09
| +0.05 / +0.84%|
The 8 analysts offering 12-month price forecasts for Keryx Biopharmaceuticals Inc have a median target of 6.50, with a high estimate of 11.00 and a low estimate of 4.00. The median estimate represents a +8.15% increase from the last price of 6.01.
The current consensus among 9 polled investment analysts is to Hold stock in Keryx Biopharmaceuticals Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.